<DOC>
	<DOCNO>NCT01213017</DOCNO>
	<brief_summary>The purpose study determine whether Certolizumab pegol rapidly reduce inflammatory change inhibit erosion hand wrist MRI patient active moderate severe rheumatoid arthritis .</brief_summary>
	<brief_title>The Effect Certolizumab Pegol MRI Synovitis Bone Edema Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>The primary objective Phase IIIb , two-center , open-label study evaluate efficacy Certolizumab pegol reduce synovitis bone edema evaluate change baseline synovitis bone edema MRI score week 6 patient moderate severe rheumatoid arthritis .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Synovitis</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>moderate severe RA ( DAS &gt; 4.4 ) least two swollen tender joint one hand/ wrist patient must fail least one nonbiologic biologic DMARDs currently receive MTX therapy concomitant diseases pathological condition could interfere impact assessment study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RAPID 3</keyword>
</DOC>